# Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain

> **NCT01167699** · PHASE3 · COMPLETED · sponsor: **Mundipharma Pharmaceuticals B.V.** · enrollment: 174 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** Oxycodone and naloxone

## Key facts

- **NCT ID:** NCT01167699
- **Lead sponsor:** Mundipharma Pharmaceuticals B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2013-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01167699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01167699, "Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01167699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*